Pictet Asset Management (Switzerland)’s Vir Biotechnology VIR Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$233K	Buy	9,481 +849	+10%	+$21.3K	﹤0.01%	1644
2023 Q1	$201K	Hold	8,632	–	–	﹤0.01%	1737
2022 Q4	$218K	Buy	+8,632	New	+$212K	﹤0.01%	1688
2022 Q3	–	Sell	-49,243	Closed	-$1.25M	–	1620
2022 Q2	$1.25M	Buy	49,243 +4,493	+10%	+$105K	﹤0.01%	1013
2022 Q1	$1.15M	Buy	44,750 +11,466	+34%	+$340K	﹤0.01%	1041
2021 Q4	$1.39M	Buy	+33,284	New	+$1.3M	﹤0.01%	1040

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s VIR Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Vir Biotechnology (VIR) stake by 9.8% in Q2 2023, buying an estimated $21.3K and bringing the position to 9,481 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #1644.

Pictet Asset Management (Switzerland) first reported a position in VIR in Q4 2021 and has held it in 6 quarters since. The position peaked at $1.39M in Q4 2021. 226 funds tracked by Wall St. Rank hold VIR as of Q2 2023.

Pictet Asset Management (Switzerland) held 9,481 shares of Vir Biotechnology worth $233K as of Q2 2023.
Pictet Asset Management (Switzerland) bought 849 Vir Biotechnology shares in Q2 2023, an estimated $21.3K.
Vir Biotechnology made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #1644 holding.
Pictet Asset Management (Switzerland) first reported a position in Vir Biotechnology in Q4 2021 and has held it in 6 quarters since.
Pictet Asset Management (Switzerland)'s Vir Biotechnology position peaked at $1.39M in Q4 2021.
226 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.